Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment
Mihai Avram, Aurore Menegaux, Felix Müller, Hannes Zaczek, Alexandra Korda, Helena Rogg, Anna M. Becker, Laura Ley, Matthias E. Liechti, Stefan Borgwardt
Cell Reports Medicine May 7, 2026 DOI: 10.1016/j.xcrm.2026.102791 via OpenAlex
Summary
AI-generated from the abstractLysergic acid diethylamide (LSD) may alleviate depression by altering white matter microstructure in the brain, potentially reflecting enhanced neuroplasticity. In a clinical trial of 61 patients with major depressive disorder, those receiving moderate-to-high doses (100 μg then 200 μg) showed increased fractional anisotropy in several white matter tracts, including the internal and external capsule, sagittal stratum, and fornix/stria terminalis. These microstructural changes correlated with improvements in depressive symptoms measured at 2, 6, and 12 weeks. The findings suggest that LSD-induced white matter changes are linked to antidepressant effects.
Study at a glance
| Characteristics | Randomized controlled trial Peer reviewed |
|---|---|
| Sample size | 35 |
| Population | Patients with major depressive disorder (MDD) |
| Intervention | Lysergic acid diethylamide (LSD) |
| Dose | 100 μg followed by 200 μg (moderate-to-high-dose) or 2 × 25 μg (low-dose) |
| Duration | 4 weeks apart (intervention), with follow-up at 2, 6, and 12 weeks |
| Topics | LSD Neuroplasticity |
| Keywords | Depression economics White matter Internal medicine |
| Citations | 1 |
| Registration | NCT03866252 |
| Key finding | LSD-induced increases in white matter fractional anisotropy correlate with improvements in depressive symptoms in patients with major depressive disorder. |
Abstract
The clinical trial NCT03866252 investigates the antidepressant effects of lysergic acid diethylamide (LSD) in 61 patients with major depressive disorder (MDD) randomized to low-dose LSD (LD-LSD; 2 × 25 μg) or moderate-to-high-dose LSD (HD-LSD; 100 μg followed by 200 μg) 4 weeks apart. Although the trial reports positive clinical outcomes, underlying mechanisms remain unclear. Here, we test whether LSD alters white matter (WM) microstructure, potentially reflecting enhanced neuroplasticity. Diffusion tensor imaging data from 35 patients (17 HD-LSD) include pre- and post-intervention scans. Voxel-wise permutation tests reveal group-by-time interactions, with increased fractional anisotropy (FA) in the internal and external capsule, sagittal stratum, and fornix/stria terminalis in the HD-LSD group. In this group, post-intervention FA values correlate with improvements in depressive symptoms at 2, 6, and 12 weeks, measured using the Inventory of Depressive Symptomatology (IDS-clinician rated [C] and IDS- self report [SR]). These findings suggest that LSD-induced WM microstructural changes are associated with antidepressant effects in MDD.